Takeovers and Blockbusters on the Horizon! Novo Nordisk, BioNxt and Bayer Keep Taking Center Stage

Bayer: A Few Portfolio Sales and EUR 2 Billion in Hybrid Capital Boost the Cash Position

Few investors had anticipated the easing of the glyphosate dispute, yet Bayer has now surged 100% in just 9 months. With a stronger cash position, things are likely to improve further, as Bayer pursues an aggressive strategy in this dynamic biotech environment to realign its finances and break free from the debt trap. The chemical and pharmaceutical giant has successfully placed new hybrid bonds worth EUR 2 billion to significantly increase its liquidity. Since leading rating agencies classify half of these bonds as equity, this move noticeably improves the key metrics that determine the company's creditworthiness.

This capital injection is accompanied by the targeted sale of portfolio assets, such as the global rights to the cancer drug Stivarga to the Aachen-based company Grünenthal. This deal will bring an additional up to EUR 375 million into the Leverkusen-based company's coffers. Together with an earlier investment from private equity firm Apollo, the group is securing the financial flexibility it needs for upcoming challenges. The primary goal of this massive liquidity drive is to refinance credit lines and address the glyphosate litigation in the US, which involves billions in claims. At the same time, the inflow of funds creates the urgently needed leeway to get its own pharmaceutical pipeline back on track. Investors are therefore reacting with visible relief to the two-pronged restructuring strategy of trimming the core portfolio and injecting fresh capital. The successful turnaround on the bond market demonstrates institutional investors' continued strong confidence in the Leverkusen-based company's financial strength. With a 2027 P/E ratio of 10.4, as calculated by LSEG analysts, the company remains undervalued even after its share price has doubled. The platform's 12-month average price target is EUR 58.70—further evidence of confidence following the recent upward momentum. Is this the starting signal for a major re-rating?

Novo Nordisk: Promising Partnership, but Patent Dispute Casts a Shadow

A similar picture emerges at Novo Nordisk. While the Danish pharmaceutical giant is skillfully navigating the volatile environment, it repeatedly has to manage a back-and-forth between forward-looking mega-deals and troublesome legal setbacks. However, the company recently pulled off a real coup with its billion-dollar collaboration with the Swedish biotech firm Nanexa. This strategic partnership secures Novo Nordisk exclusive access to a novel drug-delivery platform, which could mean that weight-loss injections will only need to be administered monthly or quarterly in the future, rather than weekly. This technological evolution opens up immense growth opportunities and could cement the company's undisputed market leadership in the booming obesity sector over the long term. One fly in the ointment, however, remains the vexing patent dispute in the US, where competitor Mylan is attempting to overturn patent protection for the popular Wegovy single-dose pens. While such attacks by generic drug manufacturers weigh on sentiment in the short term, they do little to alter the company's fundamentally excellent outlook.

For investors, the stock also stands out as the undisputed leader in the growth segment following recent price corrections, offering an extremely attractive dividend yield of over 4%. The Danish company boasts a stable dividend history and consistent increases, which is a rare mark of quality in this volatile market environment. Despite ongoing competitive pressure and political debates over pricing, its innovation pipeline remains well stocked and already promises the next five blockbuster therapies. All in all, the enormous market opportunities far outweigh the temporary regulatory hurdles, making this biotech pioneer a cornerstone of any forward-looking portfolio. Only 7 out of 30 analysts give it a thumbs-up, yet the average price target stands at DKK 317—a premium of about 25% over yesterday's price.

BioNxt Solutions: Full Steam Ahead

When it comes to drug delivery, the Canadian-German company BioNxt has a significant say in the matter. Faster than expected, BioNxt is moving closer to the crucial transition from preclinical development to clinical trials with its leading cladribine program, BNT23001. With the IMPD dossier complete, key regulatory, pharmaceutical, and manufacturing preparations are finalized, and the focus now shifts to the planned European Clinical Trial Application and, subsequently, the first human bioequivalence study with Mavenclad. The project's real appeal lies in the dosage form: BioNxt is not trying to invent a new active ingredient, but to make cladribine more convenient, and potentially more effective, through a patented sublingual oral dissolvable film. Preclinical studies have demonstrated interesting systemic drug exposure, and its transferability to humans is now the key test.

In addition, everolimus is gaining significant momentum after BioNxt prepared two of its own sublingual formulations for a comparative pharmacokinetic study in large animals. The study will compare these formulations against an orally administered 1-mg reference dose to determine whether the ODF technology actually offers advantages in terms of absorption and drug exposure. Controlled drug exposure is particularly medically relevant for everolimus, as absorption, P-glycoprotein activity, and food intake can all influence its pharmacokinetics. A meta-analysis published in 2025 of seven randomized trials involving 1,853 liver transplant recipients provides additional scientific context by linking everolimus combined with reduced tacrolimus to, among other things, a lower rate of acute rejection reactions and improved kidney function, while also pointing to increased risks of certain side effects. For BioNxt, this does not constitute proof of efficacy for its own formulation, but it does underscore the importance of delivering the active ingredient in as controlled a manner as possible.

Semaglutide simultaneously opens up a third area of development, as the company has been working since July on a sublingual ODF and, thereby, on the transferability of its technology to complex peptides. If this approach proves successful, BioNxt could eventually target other GLP-1 agonists, such as tirzepatide, and expand into a significantly larger market segment. The original cladribine story is thus increasingly evolving into a multi-asset platform, where experience gained from one development program can be applied to several established active ingredients and therapeutic areas. For large pharmaceutical companies, this very combination of patented drug-delivery technology, multiple drug candidates, and a comparatively low enterprise value of around CAD 50 million could prove attractive, making acquisition or licensing scenarios conceivable as strategic options. Extremely interesting!

The biotech sector is once again attracting attention. This is because, in the long run, it is becoming clear that the entire life sciences industry is facing a far-reaching strategic and technological reclassification. Beyond advanced active ingredients, the focus is also shifting to new dosage forms. Fundamental breakthroughs in the capital market are once again evident, as companies' cash positions are improving across the industry. It is important for investors to refine their portfolio focus while simultaneously minimizing risk.